Clinical trial · Observational
A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In recent years, immunotherapy has made significant progress in the treatment of lung cancer, especially immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) against non-small cell lung cancer (NSCLC). However, there are significant individual differences in patient response to treatment. Studies have shown that sleep disorders may affect the function of the immune system, thereby affecting tumor progression and treatment response. Therefore, the aim of this study was to evaluate the impact of sleep disturbances on lung cancer patients receiving immunotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer (NSCLC) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| PD-1 | — | UNRESOLVED | — |
| Sleep Disorders, Circadian Rhythm | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PQSI | Other | — | UNRESOLVED |
| PSQI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- lung cancer-sleep disorders
- description
- Lung cancer patients treated with PD1 immunotherapy were divided into sleep disorders and non-sleep disorders groups.
- interventionNames
- Other: PSQI
- Other: PQSI
Primary outcomes (1)
- measure
- pCR
- timeFrame
- From enrollment to the end of treatment at two years"
- description
- Pathological complete response (pCR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Diagnosis of non-small-cell lung cancer (stage II-IV) Age 18 and older Immune checkpoint inhibitor therapy (e.g., nivolumab, pembrolizumab, etc.) is planned. Be able to understand the study and provide informed consent Exclusion Criteria: Coexisting serious mental illness (e.g., major depression, anxiety, etc.) Recent chemotherapy or radiotherapy Other serious comorbidities (e.g., heart disease, liver and kidney insufficiency)
References
Publications (0)
Data not yet available